What is a mesenchymal stromal cell (MSC)? The ISCT minimal criteria
The 2006 ISCT minimal criteria set the identity standard for mesenchymal stromal cells: three positive markers, five negative markers and trilineage differentiation.

Key takeaways.
- The 2006 ISCT minimal criteria are the identity standard for MSCs.
- At least 95% of cells must express CD73, CD90 and CD105.
- CD45, CD34, CD14, CD19 and HLA-DR must be absent, meaning 2% expression or less.
- MSCs must be shown to differentiate into bone, fat and cartilage cells.
- Muscle is not part of the ISCT trilineage requirement.
- Flow cytometry is the gold standard for confirming the marker profile.
What an MSC is
Mesenchymal stem/stromal cells (MSCs) are multipotent cells, meaning they can form multiple lineages within a tissue type. The field began in the 1970s, when Alexander Friedenstein identified adherent bone marrow cells that formed colonies and could form bone and cartilage.
Because many cell preparations get called MSCs, the field uses a shared identity standard. That standard is the 2006 ISCT minimal criteria. It has three parts.
The marker profile
The first part is positive markers. At least 95% of cells must express the surface markers CD73, CD90 and CD105. This threshold separates MSCs from contaminating cell populations.
The second part is negative markers. CD45, CD34, CD14, CD19 and HLA-DR must be absent, defined as 2% expression or less. These markers rule out contamination by hematopoietic and immune cells.
Trilineage differentiation
The third part is function. The cells must be shown to differentiate into three cell types: osteoblasts (bone), adipocytes (fat) and chondrocytes (cartilage). All three are required. Myocytes (muscle) are not part of the requirement.
What the criteria do and do not tell you
Marker expression is confirmed by flow cytometry, a technique that analyses thousands of cells one by one. Product literature may name the markers without stating the 95% and 2% thresholds or showing trilineage testing. Naming markers is not the same as documenting that the criteria were met.
The criteria establish identity only. They say nothing about clinical benefit. Stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses that clinics market.
Educational content for healthcare professionals. Not a treatment recommendation. Stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses most clinics offer.
This guide covers the what and the why.
The how is taught live. The webinar and live training go deeper on:
- Reading a product's characterisation documents
- MSC biology in depth
- Questions to ask a supplier about identity testing
- How MSCs from different sources compare
Common questions.
Which markers define an MSC?
What does trilineage differentiation mean?
Does meeting the ISCT criteria mean a product is approved?
Sources
- Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015;35(2):e00191.
- Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: An update. Cell Transplant. 2016;25(5):829-48.
Keep reading.
Stem cell · 3 min read
How are MSCs thought to work? The paracrine hypothesis
Current thinking is that MSCs act mainly by secreting signalling molecules that change the local environment, not by turning into replacement tissue.
Start the lessonStem cell · 3 min read
Where do MSCs come from? Tissue sources and autologous versus allogeneic cells
MSCs can be sourced from several tissues, from the patient or from a donor. The source and the processing shape both the product and how it is regulated.
Start the lessonStem cell · 3 min read
How are stem cell products quality-checked?
Cell products are checked for identity, contamination and genetic stability. This guide explains the main tests and what each one is for.
Start the lessonReady for the hands-on detail?
Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.